Methods: Clonal populations of human OMLP-PCs (n=3) were expanded in monolayer culture. All assays were carried out +/- 100U/ml Interferon γ (IFNγ). Expression of Human Leukocyte Antigen (HLA) classes I and II on the cell surface and intracellularly were determined by FACS and Western Blotting. Mixed lymphocyte cultures (MLC) were performed +/- the T cell mitogen phytohaemagluttinin in contact and transwell systems. Data was statistically analysed by ANOVA and a Bonferroni Post-hoc test.
Results: HLA I was constitutively expressed on the cell surface of OMLP-PCs. Intracellular expression of HLA II was inducible after 24 hours of treatment with IFNγ however, cell surface expression was not detectable until day 7 of IFNγ treatment. MLCs confirmed that OMLP-PCs potently suppress lymphocyte proliferation in vitro in a concentration and contact independent manner (P<0.001 compared to controls) and that the mechanism of immunosuppression was HLA II independent.
Conclusion: This study demonstrates the potent immunosuppressive capacity of OMLP-PCs.OMLP-PCs significantly suppress lymphocyte proliferation in a concentration and contact independent manner, suggesting that these cells may be ideal candidates for allogeneic tissue engineering. These data also demonstrate the enhanced potential of OMLP-PCs for use in the treatment of immune-related disorders over MSCs that are currently being utilised.
Funding from the MRC (G0901562), NISCHR (HA09-034), BSODR and CITER is gratefully acknowledged. This work is subject to patent filing.